Circulating irisin levels in heart failure with preserved or reduced ejection fraction: A pilot study

PLoS One. 2019 Jan 18;14(1):e0210320. doi: 10.1371/journal.pone.0210320. eCollection 2019.


Irisin, a recently discovered myokine, has been considered a prognostic factor in several cardiovascular diseases. Nevertheless, no data are available on the role of irisin in patients with heart failure (HF), both with preserved (HFpEF) or reduced (HFrEF) ejection fraction. We have therefore evaluated the circulating irisin levels in HFpEF and HFrEF patients, correlating them with metabolic parameters and total antioxidant capacity (TAC), as index of oxidative stress. Irisin was significantly higher in HFpEF than in HFrEF patients (7.72 ± 0.76 vs 2.77 ± 0.77 ng/ml, respectively). An inverse correlation between irisin and TAC was found in HFpEF, but not in HFrEF. Conversely, no correlation was present with HOMA index. These data support the hypothesis that a different pathophysiological mechanism is involved in the two HF subtypes, and oxidative stress modulates irisin secretion.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Fibronectins / blood*
  • Heart Failure / blood*
  • Heart Failure / physiopathology*
  • Humans
  • Insulin Resistance
  • Logistic Models
  • Male
  • Middle Aged
  • Oxidative Stress
  • Pilot Projects
  • Stroke Volume / physiology*


  • FNDC5 protein, human
  • Fibronectins

Grant support

The authors received no specific funding for this work.